Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Man Kyu | - |
dc.contributor.author | Moon, Yujeong | - |
dc.contributor.author | Yang, Suah | - |
dc.contributor.author | Kim, Jinseong | - |
dc.contributor.author | Cho, Hanhee | - |
dc.contributor.author | Lim, Seungho | - |
dc.contributor.author | Yoon, Hong Yeol | - |
dc.contributor.author | Seong, Joon-Kyung | - |
dc.contributor.author | Kim, Kwangmeyung | - |
dc.date.accessioned | 2021-08-30T07:11:14Z | - |
dc.date.available | 2021-08-30T07:11:14Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/51394 | - |
dc.description.abstract | Chemotherapy has shown remarkable therapeutic efficacy for various types of cancer. However, drug resistance reduces the effectiveness and sensitivity of chemotherapy, leading treatment failure and cancer relapse in many clinical indications. Herein, we propose cancer-specific drug-drug nanoparticles (DD-NPs) that improve the therapeutic efficacy of chemotherapy against drug-resistant cancer. Cancer-specific and pro-apoptotic drug-drug conjugate was prepared by conjugating the pro-apoptotic peptide drug (SMAC; Ala-Val-Pro-Ile-Ala-Gin, AVPIAQ) and cathepsin B-cleavable peptide (Phe-Arg-Arg-Gly, FRRG) to a doxorubicin (DOX), resulting in SMAC-FRRGDOX that allows self-assembled into nanoparticles. The resulting DD-NPs were specifically cleaved to proapoptotic SMAC and cytotoxic DOX only in cathepsin B-overexpressing cancer cells, inducing a synergy of the pro-apoptotic activity with the chemotherapy. In MCF-7 breast tumor-bearing mice, intravenously injected DD-NPs highly accumulated at targeted tumor tissues via enhanced permeability and retention (EPR) effect, releasing SMAC and DOX, which showed a synergetic pro-apoptotic/chemotherapy. Furthermore, DD-NPs greatly suppressed tumor growth and improved overall survival in a metastatic lung cancer model. Collectively, these cancer-specific drug-drug nanoparticles may be a promising strategy to treat drug-resistant cancers with high cancer cell-specificity. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | BREAST-CANCER | - |
dc.subject | DELIVERY | - |
dc.subject | PROTEINS | - |
dc.subject | TEMOZOLOMIDE | - |
dc.subject | INHIBITOR | - |
dc.subject | TARGETS | - |
dc.subject | DESIGN | - |
dc.title | Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seong, Joon-Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Kwangmeyung | - |
dc.identifier.doi | 10.1016/j.biomaterials.2020.120347 | - |
dc.identifier.scopusid | 2-s2.0-85090028475 | - |
dc.identifier.wosid | 000576748600003 | - |
dc.identifier.bibliographicCitation | BIOMATERIALS, v.261 | - |
dc.relation.isPartOf | BIOMATERIALS | - |
dc.citation.title | BIOMATERIALS | - |
dc.citation.volume | 261 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | PROTEINS | - |
dc.subject.keywordPlus | TEMOZOLOMIDE | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | TARGETS | - |
dc.subject.keywordPlus | DESIGN | - |
dc.subject.keywordAuthor | Drug resistance | - |
dc.subject.keywordAuthor | Prodrug | - |
dc.subject.keywordAuthor | Cancer nanomedicine | - |
dc.subject.keywordAuthor | Synergetic effect | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.